{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:06:45Z","timestamp":1785442005767,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004313","name":"General Electric","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012309","name":"Nortel Networks Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012309","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.numecd.2025.104036","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T08:43:44Z","timestamp":1744015424000},"page":"104036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1066-9002","authenticated-orcid":false,"given":"Ilana S.","family":"Golub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkat S.","family":"Manubolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo","family":"Aldana-Bitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiran","family":"Verghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luay","family":"Alalawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Kianoush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Benzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Kinninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooman","family":"Fazlalizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leili","family":"Pourafkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadije","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriraj","family":"Susarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Czarina","family":"Mangaoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed K.","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise Alison","family":"Javier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Hamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sion K.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Budoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2025.104036_bib1","first-page":"851","volume":"7","author":"Riazi","year":"2022","journal-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.numecd.2025.104036_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011295","article-title":"Diabetes mellitus\u2013related all\u2010cause and cardiovascular mortality in a national cohort of adults","volume":"8","author":"Raghavan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2025.104036_bib3","first-page":"135","volume":"9","author":"Caturano","year":"2021","journal-title":"Non-AlcoholicFatty Liver Disease: From Pathogenesis to Clinical Impact. Processes"},{"key":"10.1016\/j.numecd.2025.104036_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112091","article-title":"Comprehensive study of the interplay between immunological and metabolic factors in hepatic steatosis","volume":"133","author":"Banerjee","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.numecd.2025.104036_bib5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.numecd.2025.104036_bib6","first-page":"328","volume":"67","author":"Chalasani","year":"2018","journal-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology"},{"key":"10.1016\/j.numecd.2025.104036_bib7","unstructured":"Caturano, A., et al."},{"key":"10.1016\/j.numecd.2025.104036_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.37349\/emed.2020.00019","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin","volume":"1","author":"Acierno","year":"2020","journal-title":"Explor. Med."},{"issue":"1","key":"10.1016\/j.numecd.2025.104036_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12933-024-02171-9","article-title":"Fatty liver index is an independent risk factor for all-cause mortality and major cardiovascular events in type 1 diabetes: an 11-year observational study","volume":"23","author":"Garofolo","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.numecd.2025.104036_bib10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.numecd.2025.104036_bib11","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"19","key":"10.1016\/j.numecd.2025.104036_bib12","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104036_bib13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.numecd.2025.104036_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2025.104036_bib15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2025.104036_bib16","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"19","key":"10.1016\/j.numecd.2025.104036_bib17","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.numecd.2025.104036_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"LEADER steering committee; LEADER trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104036_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2018.03.030","article-title":"Harmony Outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics","volume":"203","author":"Green","year":"2018","journal-title":"Am Heart J"},{"issue":"10193","key":"10.1016\/j.numecd.2025.104036_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.numecd.2025.104036_bib21","first-page":"306","volume":"31","author":"Hamal","year":"2020","journal-title":"Effect of semaglutide on coronary atherosclerosis progression in patients with type II diabetes: rationale and design of the semaglutide treatment on coronary progression trial. Coron Artery Dis"},{"issue":"2","key":"10.1016\/j.numecd.2025.104036_bib22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1148\/radiol.2021204288","article-title":"Quantification of liver fat content with CT and MRI: state of the art","volume":"301","author":"Starekova","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.numecd.2025.104036_bib23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/gastroent15030043","article-title":"Grading of fatty liver based on computed tomography Hounsfield unit values versus ultrasonography grading","volume":"15","author":"Alshoabi","year":"2024","journal-title":"Gastroenterol Insights"},{"issue":"7","key":"10.1016\/j.numecd.2025.104036_bib24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.acra.2012.02.022","article-title":"Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis","volume":"19","author":"Zeb","year":"2012","journal-title":"Acad Radiol"},{"key":"10.1016\/j.numecd.2025.104036_bib25","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"HighPrevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma Aminotransferase levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2025.104036_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13372","article-title":"The incretin\/glucagon system as a target for pharmacotherapy of obesity","volume":"23","author":"Del Prato","year":"2022","journal-title":"Obes Rev"},{"key":"10.1016\/j.numecd.2025.104036_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coph.2016.08.005","article-title":"GLP-1 as a target for therapeutic intervention","volume":"31","author":"Rajeev","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.numecd.2025.104036_bib28","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-\/- and LDLr-\/- Mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC. Basic. Transl. Sci."},{"key":"10.1016\/j.numecd.2025.104036_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.numecd.2025.104036_bib30","first-page":"545","volume":"18","author":"Piro","year":"2008","journal-title":"Molecular determinants of insulin resistance, cell apoptosis and lipid accumulation in non-alcoholic steatohepatitis. Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.numecd.2025.104036_bib31","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"NN9931-4296Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104036_bib32","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1210\/jc.2015-3906","article-title":"Mechanisms of action of liraglutide in patients with type 2 diabetes treated with high-dose insulin","volume":"101","author":"Vanderheiden","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2025.104036_bib33","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD study","volume":"102","author":"Petit","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2025.104036_bib34","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2025.104036_bib35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325001905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325001905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:39:25Z","timestamp":1762331965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475325001905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0939475325001905"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104036","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}],"article-number":"104036"}}